• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Patients satisfied with improved contrast sensitivity of IOL

Article

Philadelphia-The Tecnis Z9000 IOL (Pharmacia) performed well in a clinical trial by providing improved contrast sensitivity compared with a conventional IOL. In addition, in a model eye the Tecnis IOL also improved the optical performance by compensating for corneal aberrations.

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
Related Content
Study evaluates the potential correlation of ultra-processed food consumption and increased glaucoma incidence

Study evaluates the potential correlation of ultra-processed food consumption and increased glaucoma incidence

Article
Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures

(EyePod) From idea to impact: Navigating ophthalmic innovation

Podcast
Treatment challenges in patients with nAMD

Treatment challenges in patients with nAMD

Article
EyePod: Modifier Gene Therapy: What is it?

EyePod: Modifier Gene Therapy: What is it?

Podcast
The evolving role of vitreosurgical simulators in surgical training

The evolving role of vitreosurgical simulators in surgical training

Article
Kiora Pharmaceuticals receives grant to fund novel clinical trial endpoints for inherited retinal diseases

Kiora Pharmaceuticals receives grant to fund novel clinical trial endpoints for inherited retinal diseases

Article
© 2024 MJH Life Sciences

All rights reserved.